FindTrial
Sign In

Efficacy and Safety of Vildagliptin in Type 2 Diabetes

Effectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus Real World Evidence in Indian patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/01/039112
Enrollment
2000
Registered
2022-01-04
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Cipla Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: all patients treated with metformin XR on total daily dose of at least 1000 mg

Exclusion criteria

Exclusion criteria: those with hypersensitivity reactions pregnancy lactation or other contraindications for use of vildagliptin

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is Change in Glycated haemoglobin HbA1c from baseline to end of 3 monthsTimepoint: 3 months—

Secondary

MeasureTime frame
efficacy and tolerability evaluatedTimepoint: 3 months—

Countries

India

Contacts

Public ContactDr Shwetal Sanghvi

Insignia Communications Pvt Ltd

drshwetal@insigniacom.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026